Quantitative analysis for Kailera Therapeutics, Inc. (KLRA) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (34.0) (grade D). 27 signals analyzed (23 differentiated alt-data).
KLRA stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $24.32 | $22.95 | $23.82 |
| 2026-05-08 | $24.27 | $21.22 | $21.47 |
| 2026-05-20 | $20.79 | $19.58 | $20.07 |
| 2026-06-02 | $23.98 | $22.30 | $22.59 |
| 2026-06-12 | $20.33 | $18.69 | $18.89 |
| 2026-06-25 | $21.45 | $20.20 | $20.66 |
| 2026-07-08 | $22.34 | $20.31 | $21.76 |
| 2026-07-20 | $18.98 | $17.87 | $17.91 |
| 2026-07-30 | $17.26 | $16.50 | $17.05 |
| 2026-08-12 | $19.06 | $18.23 | $18.59 |
| 2026-08-24 | $17.16 | $16.37 | $16.54 |
| 2026-09-03 | $16.51 | $15.50 | $15.74 |
How Kailera Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $2.1B | 65.0 |
| ZLAB | Zai Lab Limited | $2.1B | 35.0 |
| MMED | MiniMed Group, Inc. Common Stock | $3.3B | — |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | — |
View all Health Care stocks by valuation and signals →
Kailera Therapeutics, Inc. (KLRA) scores Sell (34.0), and the composite conceals a 86-point disagreement between its dimensions. It is strongest on analyst consensus at 96, and weakest on competitive moat at 27 and technicals at 10. A stock can carry analyst consensus that high while technicals sits at 10; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 96 |
| competitive moat | 27 |
| technicals | 10 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Kailera Therapeutics, Inc. (KLRA): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/KLRA"><img src="https://stoquant.com/badge/KLRA.svg" alt="Kailera Therapeutics, Inc. (KLRA) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.